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Age older than 65 years, hemoglobin level
lower than 100 g/L (10 g/dL), white blood
cell count greater than 25  109/L, periph-
eral blood blasts 1% or higher, and consti-
tutional symptoms have been shown to
predict poor survival in primary myelofi-
brosis (PMF) at diagnosis. To investigate
whether the acquisition of these factors
during follow-up predicts survival, we
studied 525 PMF patients regularly fol-
lowed. All 5 variables had a significant
impact on survival when analyzed as time-
dependent covariates in a multivariate
Cox proportional hazard model and were
included in 2 separate models, 1 for all
patients (Dynamic International Prognos-
tic Scoring System [DIPSS]) and 1 for
patients younger than 65 years (age-
adjusted DIPSS). Risk factors were as-
signed score values based on hazard
ratios (HRs). Risk categories were low,
intermediate-1, intermediate-2, and high
in both models. Survival was estimated
by the HR. When shifting to the next risk
category, the HR was 4.13 for low risk,
4.61 for intermediate-1, and 2.54 for
intermediate-2 according to DIPSS; 3.97
for low risk, 2.84 for intermediate-1, and
1.81 for intermediate-2 according to the
age-adjusted DIPSS. The novelty of
these models is the prognostic assess-
ment of patients with PMF anytime dur-
ing their clinical course, which may be
useful for treatment decision-making.
(Blood. 2010;115:1703-1708)
Introduction
Primary myelofibrosis (PMF) is a Philadelphia-negative myelopro-
liferative neoplasm (MPN) whose diagnostic criteria have been
recently updated.1 Among MPNs, PMF has the most heterogeneous
clinical presentation, which may encompass anemia, spleno-
megaly, leukocytosis or leukopenia, thrombocytosis or thrombocy-
topenia, and constitutional symptoms. The discovery of the activat-
ing mutation JAK2 (V617F) in more than 70% of patients with
MPNs2 led to the development of new biochemically selective
JAK2 inhibitors.3 These agents are currently being tested in clinical
trials that usually include patients with long disease history.
Advanced age,4-7 anemia,4-11 red blood cell transfusion
need,12 leukopenia,8 leukocytosis,8 thrombocytopenia,9 periph-
eral blast count,4,6 systemic symptoms,6,10 degree of microvessel
density,13 and cytogenetic abnormalities5,7,9,14-16 were shown to
be associated with poor outcome in patients with PMF. The
presence of the JAK2 (V617F) mutation per se does not seem to
imply worse survival,17 although a low JAK2 (V617F) allele
burden seems associated with poorer outcome.18,19 Recently,
Cervantes et al17 on behalf of the International Working Group
for Myeloproliferative Neoplasms Research and Treatment
(IWG-MRT) developed a prognostic scoring system to estimate
survival of PMF patients. This model uses 5 factors (age older
than 65 years, hemoglobin level  100 g/L [10 g/dL], white
blood cell count  25  109/L, peripheral blood blasts  1%,
and presence of constitutional symptoms) to identify 4 risk
categories with different survival.
Prognostic models for PMF developed so far are based on the
evaluation of risk factors present at diagnosis. However, the
acquisition of additional risk factors during the disease course may
substantially modify the patients’ outcome. A dynamic prognostic
model that accounts for modifications of the risk profile after
diagnosis may prove useful in clinical practice. On behalf of
IWG-MRT, first we investigated whether the acquisition anytime
during follow-up of one or more of the prognostic factors
identified by Cervantes et al17 predicts survival. Then, a new
prognostic score based on a time-dependent risk evaluation was
developed: the Dynamic International Prognostic Scoring Sys-
tem (DIPSS) for PMF.
Methods
The study was carried out through an international cooperation on
behalf of the IWG-MRT. An ad hoc database was developed for data
collection.
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Study design
The Institutional Review Board of each participating center approved the
study, and the procedures followed were in accordance with the Declaration
of Helsinki. The objective of the study was the definition of a dynamic
prognostic model to predict survival in PMF. The end points of the study
were time to acquisition of the selected risk factors and survival.17 Risk
factors were age older than 65 years, hemoglobin level lower than 100 g/L
(10 g/dL), white blood cell count greater than 25 109/L, peripheral blood
blasts equal to or greater than 1%, and presence of constitutional symptoms
( 10% weight loss in 6 months, night sweats, unexplained fever higher
than 37.5°C). For each patient, the date of acquisition of these risk factors
during follow-up was registered. The inclusion criteria were (1) diagnosis
of PMF based on the presence of megakaryocyte proliferation and atypia
accompanied by increased reticulin and/or collagen in bone marrow as
major criterion, as well as of the JAK2 (V617F) or the MPL mutations if
available and 2 criteria among anemia, splenomegaly, increased lactate
dehydrogenase activity, and leukoerythroblastosis; (2) diagnosis performed
between 1980 and 2008; (3) regular follow-up of the patients at each
institution (at least 3 visits a year); (4) disease-related acquisition of risk
factors, leukocytosis, peripheral blastosis, and constitutional symptoms
should be recorded at the time of their first occurrence, whereas hemoglobin
level should be permanently lower than 100 g/L (10 g/dL) and not due to
treatment toxicity. Patients with post–polycythemia vera and post–essential
thrombocythemia myelofibrosis20 and those with diagnosis of “prefibrotic”
myelofibrosis21 were excluded.
Statistical analysis
Continuous variables are summarized as median and range. Categoric
variables are described by count and relative frequency of each category
(%). Comparison of continuous baseline features between patients of
different participating centers was carried out by Kruskal-Wallis nonpara-
metric analysis of variance. Categoric features were compared using the
2 test for tables. Analyses of time to acquisition of a risk factor were
performed considering death as a competing risk.22,23 Survival analysis was
carried out with either the Kaplan-Meier method when investigating a
single categoric risk factor or Cox proportional hazard regression, with and
without dichotomous time-dependent covariates, when performing multivar-
iate analysis. The log-rank test was applied to compare Kaplan-Meier
curves; a test for trend was also used when applicable. Wald test was used to
assess the significance of covariates in Cox models. Statistical analyses
were performed using Microsoft Excel 2000, Statistica 8 (Stat-Soft Inc),
Stata SE 9.2 (StataCorp), and R 2.9.2 (The R Foundation for Statistical
Computing).
Results
Initial characteristics and clinical course
The main clinical characteristics at diagnosis of the 525 patients are
reported in Table 1. Comparing the distribution of clinical features
at diagnosis among different centers, only results for age were
significantly different (P  .001).
During follow-up, 335 patients (64%) received palliative cytore-
ductive therapies after a median time of 0.3 years (range,
0-20.4 years) from diagnosis. Prednisone was given to 187 patients
(36%), androgens to 88 (16%), and erythropoietin to 57 (11%) after
a median time of 0.5 years (range, 0-18.7 years), 0.9 years (range,
0-18.7 years), and 1.6 years (range, 0-17.1 years), respectively.
Splenectomy was performed in 46 (9%) patients after a median
time of 1.7 years (range, 0-11 years) from diagnosis. Eight patients
underwent allogeneic stem cell transplantation (SCT) after a
median of 2.2 years (range, 1-5.6 years) from diagnosis and were
censored at the time of bone marrow transplantation. Acute
leukemia, with a threshold of 20% peripheral blast cells, occurred
in 70 patients (13%). A total of 277 (53%) patients died. Known
causes of death were disease evolution in 63 patients (40%),
disease related in 22 (13%), infection in 25 (16%), bleeding in
19 (12%), transplant related in 3 (2%), congestive heart failure in
18 (11%), and cancer in 10 (6%).
We tested the Cervantes et al score in our series of 525 patients
with PMF. Median survival was 14.6 years in low-risk patients,
7.4 years in intermediate-1, 4 years in intermediate-2, and 2.3 years
in high risk (Figure 1). Survival was significantly different among
the 4 risk categories (P  .001).
Acquisition of risk factors during follow-up
To investigate the dynamics of the acquisition of each risk factor
during follow-up, we evaluated the rate of occurrence, the time to
acquisition, and the association with characteristics at diagnosis.
Only patients who did not present the risk factor at diagnosis were
included. Overall, 68 (26%) patients passed the 65-year age
threshold, 158 (47%) developed marked anemia (Hb  100 g/L
[10 g/dL]), 72 (15%) developed leukocytosis (white blood cell
[WBC] count  25  109/L), 102 (27%) had 1% or higher
peripheral blast cells, and 54 (14%) had constitutional symptoms.
Cumulative incidence analysis, with death as a competing risk,
showed that the median anemia-free survival from diagnosis was
7.6 years (Figure 2A). According to proportional hazards multivari-
able regression, advanced age (P  .014), higher leukocyte count
(P  .019), and lower hemoglobin level (P  .001) at diagnosis
had an independent impact on the incidence of anemia. The
cumulative incidence of leukocytosis was 21.6% at 15 years
Table 1. Demographic and hematologic characteristics at diagnosis
of 525 patients with primary myelofibrosis
Characteristic Value
No. of patients 525
Median follow-up, y (range) 3.3 (0.6-24)
Age younger than 65 y (%) 262 (49)
Male/female 335/190
White blood cell count greater than 25  109/L (%) 55 (10)
Hemoglobin level lower than 10 g/dL (%) 188 (36)
Platelet count lower than 100  109/L (%) 83 (16)
Peripheral blast cells 1% or higher (%) 144 (27)
Constitutional symptoms (%) 144 (27)
Splenomegaly (%) 434 (83)
Hepatomegaly (%) 343 (65)
Figure 1. Validation of the Cervantes et al score in 525 patients with primary
myelofibrosis. The Cervantes et al score has been validated in 525 patients with
primary myelofibrosis. The score was able to classify patients at diagnosis into
4 categories with a significantly different survival (P  .001).
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(Figure 2B). Advanced age (P  .032) and higher leukocyte count
(P  .001) were independent prognostic factors for the acquisition
of leukocytosis by multivariable analysis. The cumulative inci-
dence of blast excess was 38.7% at 15 years (Figure 2C). Higher
leukocyte count (P  .01) and lower platelet count (P  .01)
independently affected blast-free survival. The cumulative inci-
dence of constitutional symptoms was 22.2% at 15 years (Figure
2D) with age (P  .03) having an independent impact on the
incidence of constitutional symptoms.
Impact of time-dependent covariates on survival
We performed univariate survival analysis by Cox regression
models using age older than 65 years, hemoglobin less than
100 g/L (10 g/dL), white blood cell count greater than 25 109/L,
peripheral blood blasts equal to or greater than 1%, and the
presence of constitutional symptoms as time-dependent covariates.
The hazard ratios (HRs) were 2.6 (95% confidence interval [CI]:
2.04-3.45; P  .001) for age, 3.57 (95% CI: 2.78-4.58; P  .001)
for white blood cell count, 6.74 (95% CI: 4.93-9.21; P  .001) for
hemoglobin, 3.55 (95% CI: 2.77-4.56; P  .001) for peripheral
blood blasts, and 3.03 (95% CI: 2.60-4.20; P  .001) for constitu-
tional symptoms. In a multivariable Cox proportional hazard
regression, all variables retained statistical significance on survival
(Table 2) and were therefore included in the dynamic model.
DIPSS model
As a first step, we assessed the validity of the Cervantes et al
score17 as a time-dependent variable. This 4-category score,
which gives the same weight to each risk factor, had a significant
prognostic effect on survival (P  .001). However, the high HR
associated with the acquisition of anemia by multivariable
time-dependent Cox regression (Table 2) prompted us to assign
a different weight to this parameter. We therefore defined a new
scoring system (Table 3) by assigning each factor (age
 65 years, hemoglobin level  100 g/L [10 g/dL], white blood
cell count  25  109/L, peripheral blood blasts  1%, and
presence of constitutional symptoms) an integer weight close to
the corresponding HR in the time-dependent multivariable Cox
regression. To assess the prognostic impact of the resulting
score, we included the score as a continuous time-dependent
covariate in a Cox survival regression model. The HR was 1.94
(95% CI: 1.79-2.11, P  .001), that is, there is a 1.94-fold
increase in hazard when the patient acquires each score value at
any time from diagnosis. Kaplan-Meier survival curves (supple-
mental Figure 1, available on the Blood website; see the
Supplemental Materials link at the top of the online article)
corresponding to the 6 score values were significantly different
by log-rank test and test for trend (P  .001). To facilitate the
implementation of the score in clinical practice, we recoded it
into 4 broader categories of adequate numerosity by pooling
consecutive score values. The resulting risk categories are low
(score  0), intermediate-1 (score 1 or 2), intermediate-2 (score
3 or 4), and high (score 5 or 6). Median survival was not reached
in low-risk patients; it was 14.2 years in intermediate-1, 4 years
in intermediate-2, and 1.5 years in high risk (Figure 3). We
analyzed the categoric DIPSS score as a time-dependent covari-
ate in a Cox survival regression model. The estimated HRs were
4.13 (95% CI: 1.73-9.82; P  .001) if the risk category shifted
from low to intermediate-1, 4.61 (95% CI: 3.18-9.82; P  .001)
from intermediate-1 to intermediate-2, and 2.54 (95% CI:
1.94-3.31; P  .001) from intermediate-2 to high.
Figure 2. Cumulative incidence of acquisition of risk
factors during follow-up, estimated with death as a
competing risk in patients with primary myelofibro-
sis. The cumulative incidence of each risk factor has
been calculated considering only patients who did not
have the risk factor at diagnosis. (A) Time to anemia
(hemoglobin  100 g/L [10 g/dL]). (B) Time to leukocyto-
sis (WBC count  25  109/L). (C) Time to blastosis
(peripheral blood blasts 1%). (D) Time to constitutional
symptoms.
Table 2. Multivariable Cox proportional hazard regression with
time-dependent covariates in primary myelofibrosis for all ages and
age younger than 65 years
Time-dependent covariate HR 95% CI P
All patients
Age older than 65 y 1.98 1.52-2.60  .001
WBC count greater than 25  109/L 1.74 1.33-2.29  .001
Hb level lower than 10 g/dL 4.18 3.03-5.78  .001
Peripheral blood blasts 1% or higher 1.82 1.39-2.40  .001
Constitutional symptoms 2.06 1.61-2.65  .001
Patients younger than 65 y
WBC count greater than 25  109/L 1.7 1.01-2.95 .048
Hb level lower than 10 g/dL 3.7 2.11-6.51  .001
Peripheral blood blasts 1% or higher 2.59 1.65-4.06  .001
Constitutional symptoms 3.04 1.93-4.80  .001
HR indicates hazard ratio; WBC, white blood cell; and Hb, hemoglobin.
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Age-adjusted DIPSS model
Because the age limit for treating patients using allogeneic SCT is
set at 65 years, we developed an age-adjusted DIPSS (aaDIPSS)
for younger patients (age  65). In a multivariable Cox propor-
tional hazard survival analysis, all covariates (hemoglobin level
 100 g/L [10 g/dL], white blood cell count 25  109/L, periph-
eral blood blasts  1%, and presence of constitutional symptoms)
were independent risk factors (Table 3), so they were all included in
the aaDIPSS. We assigned integer score weights close to the
corresponding HR (Table 4). When testing the score as a continu-
ous time-dependent covariate in a Cox survival regression model,
the resulting HR was 1.95 (95% CI: 1.68-2.27, P  .001), meaning
a 1.95-fold increase in hazard when the patient acquires each score
value at any time from diagnosis. By comparing the Kaplan-Meier
survival curves corresponding to the 7 score values, both log-rank
test (P  .001) and the test for trend (P  .001) gave significant
results (supplemental Figure 2). We merged consecutive score
values into 4 risk categories: low (score 0), intermediate-1 (score
1 to 2), intermediate-2 (score 3 to 4), and high (score 4). Median
survival was not reached in low-risk patients; it was 9.8 years in
intermediate-1, 4.8 years in intermediate-2, and 2.3 years in high
risk (Figure 4). To investigate the prognostic role of the aaDIPSS
score on survival, we analyzed the score as a categoric time-
dependent covariate in a Cox survival regression model. The HR
was 3.97 (95% CI: 1.5-10.5, P  .005) when category shifted from
low to intermediate-1, 2.84 (95% CI: 1.46-5.54; P  .002) from
intermediate-1 to intermediate-2, and 1.81 (95% CI: 1.08-3.04;
P  .025) from intermediate-2 to high.
Discussion
The IWG-MRT has recently developed a prognostic model for
primary myelofibrosis based on 5 factors at diagnosis: age older
than 65 years, hemoglobin lower than 100 g/L (10 g/dL), white
blood cell count greater than 25 109/L, peripheral blood blasts
equal to or greater than 1%, and constitutional symptoms.17
Although this scoring system remains a milestone in the prognosti-
cation of PMF, this model is applicable only to stratify patients at
the time of diagnosis, given that it does not account for the effect of
time changes of risk factors on survival.
Therefore, the goal of the new project of the IWG-MRT was to
develop a dynamic prognostic model to classify patients with PMF
into prognostic categories anytime according to recognized clinical
features. This task was accomplished by evaluating patients
followed on a regular basis, which means at least 3 visits a year.
The DIPSS incorporates all risk factors identified at diagnosis by
prior IWG-MRT study.17 These were also statistically significant
when analyzed as time-dependent covariates in a multivariate Cox
model. This approach showed that the acquisition of anemia over
time affects survival with a HR roughly double than that of other
parameters. This allows us to assign a greater weight to anemia in
the score. Therefore, DIPSS differs from the Cervantes et al score,
which gave the same weight to each risk factor. Comparing the
2 models, the time-dependent analysis confers a higher prognostic
power to anemia. This is likely because anemia is the risk factor
acquired most frequently and earlier during follow-up. The toxic
effect of cytoreductive therapy on anemia should be ruled out,
according to the inclusion criteria of the study. We presume that the
relationship between the acquisition of anemia during follow-up
Figure 3. Kaplan-Meier estimate of survival in primary myelofibrosis according
to the DIPSS. Risk categories were according to the score obtained anytime during
follow-up. Low risk: score 0, intermediate-1 risk: score 1-2; intermediate-2 risk: score
3-4, and high risk: score 5-6.
Figure 4. Kaplan-Meier estimate of survival in primary myelofibrosis according
to the aaDIPSS. Risk categories were according to the score obtained at any time
during follow-up. Low risk: score 0, intermediate-1 risk: score 1-2; intermediate-2 risk:
score 3-4; and high risk: score 4.
Table 3. DIPSS for survival in primary myelofibrosis
Prognostic variable
Value
0 1 2
Age, y  65  65
White blood cell count,109/L  25  25
Hemoglobin, g/dL  10  10
Peripheral blood blast, %  1  1
Constitutional symptoms, Y/N N Y
The risk category is obtained adding up the values of each prognostic variable.
Risk categories are defined as low: 0; intermediate-1: 1 or 2; intermediate-2: 3 or 4;
and high: 5 or 6.
DIPSS indicates Dynamic International Prognostic Scoring System.
Table 4. Age-adjusted DIPSS for survival in primary myelofibrosis
Prognostic variable
Value
0 1 2
White blood cell count,109/L  25  25
Hemoglobin, g/dL  10  10
Peripheral blood blast, %  1  1
Constitutional symptoms, Y/N N Y
The risk category is obtained adding up the values of each prognostic variable.
Risk categories are defined as low: 0; intermediate-1: 1 or 2; intermediate-2: 3 or 4;
and high: more than 4.
DIPSS indicates Dynamic International Prognostic Scoring System.
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and worse outcome is due mainly to disease progression. This
information might drive early therapeutic intervention to correct
anemia. In the DIPSS, anemia reflects myelodepletion, whereas
other parameters involve other aspects of the disease such as
myeloproliferation (leukocytes  25  109/L; peripheral blood
blasts  1%), the patient’s response to the illness (constitutional
symptoms), the patient’s ability to tolerate intensive therapy (age),
and the impact of comorbidities (age). Recently, a correlation
between low JAK2 (V617F) allele burden, myelodepletive pheno-
type, and shortened survival has been proved in PMF.18 Investiga-
tors also provided evidence of a relationship between low JAK2
mutant allele burden and shorter time to anemia and to leukopenia.
This JAK2-based prognostic model supports the negative impact of
anemia on survival in PMF.
The advantage of a time-dependent analysis of survival is
basically a realistic definition of risk categories, compared with a
nondynamic analysis.24 In a non–time-dependent analysis, patients
are assigned to a risk group on the basis of the assessment of risk
factors at diagnosis, and are followed in the same category
irrespective of the acquisition of other risk factors during disease
course. In PMF, this is the case of the Cervantes et al score (Figure
1). According to a dynamic model, patients contribute to the
estimate of survival in a score category only as long as they do not
acquire further risk factors; then they shift to a higher score
category. This is the case of the DIPSS (Figure 3). Survival curves
obtained by the 2 different models are not directly comparable.
However, differences in survival obtained with the 2 approaches
are evident, especially in the case of low- and intermediate-1–risk
categories. This is not surprising, as patients at low risk according
to DIPSS are those who do not acquire a risk factor throughout
follow-up, in contrast to those at low risk according to the
Cervantes et al score. The discrepancy between high-risk catego-
ries of the 2 scoring systems seems lower, although still present.
Therefore, keeping in mind the different basis of the 2 models, we
may use the Cervantes et al score at diagnosis and the DIPSS
anytime during the course of the disease.
From a practical point of view, anytime a decision has to be
made on the basis of an updated prognostic status, the parameters
of the DIPSS models will be checked and corresponding values
will be assigned (Tables 3-4). The sum of the values will allow
allocating the patient into a risk category (low, intermediate-1,
intermediate-2, high). Cumulative survival can be estimated from
the Kaplan-Meier curves. The corresponding cumulative probabil-
ity of survival at each time point of the follow-up should be read in
Figures 3 and 4 considering the time elapsed since diagnosis. This
estimate remains applicable thereafter until a patient changes risk
category. The increased risk when changing risk category can be
estimated as a HR (Figures 3-4).
We developed separate models, one for all patients (the
DIPSS) and one for patients younger than 65 years (the
aaDIPSS), both applicable during the course of the disease. On
the basis of modification of the DIPSS, a new calculation of life
expectancy may be made and alternative treatment approaches
may be considered. After the discovery of the JAK2 and MPL
mutations, new molecules with anti-JAK2 properties have
undergone preclinical testing and some are being investigated in
clinical trials.25 The majority of these phase 2 trials include
patients in advanced phases of the disease with a risk status
different from that assessed at diagnosis. DIPSS may permit
assignment of patients to the updated risk profile, therefore
allowing appropriate patient selection. This model would also
allow meaningful comparison of the results of different trials
and definition of the role of new drugs in specific risk categories.
Until now, the only potentially curative approach resulting in
prolongation of survival is allogeneic SCT.26-30 This option may
be offered to patients younger than 65 years, in whom the
morbidity and mortality associated with the procedure must be
balanced with the patient’s life expectancy. In fact, a recent
prospective multicenter study on allogeneic SCT after reduced-
intensity conditioning included patients with an age ranging
from 32 to 68 years (median, 55 years).30 In this context, the
aaDIPSS may help in decision-making. As the age limit for
transplantation is a moving target, we suggest applying DIPSS
for fit patients older than 65 years, because this score also
accounts for older age.
The dynamic models may also provide a framework for studies
on the prognostic role of genetic markers in PMF.
In conclusion, this study shows that age older than 65 years,
hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25 109/L, peripheral blood blasts equal to or
greater than 1%, and constitutional symptoms predict survival
independently and in a time-dependent manner in patients with
PMF. The novelty of DIPSS and aaDIPSS is the prognostic
assessment of PMF patients anytime during clinical course with a
useful implication for clinical decision-making.
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